Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2018-09-28 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-09-28 English
DEF 14A
Proxy Solicitation & Information Statement
2018-09-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated September 4, 2018, from Aeglea BioTherapeutics, Inc. It reports a Regulation FD Disclosure about an enrollment status update and new interim Phase 1/2 clinical trial data, including a press release and presentation poster attached as exhibits. The document explicitly states it is a "Current Report" under the Securities Exchange Act of 1934 and includes no financial statements or detailed financial analysis. The content is an announcement of new information rather than a full financial report or earnings release. Given the nature of the filing (Form 8-K) and the content (disclosure of clinical trial data and press release), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is under 5,000 characters, and it includes attachments but does not contain the full report itself, so it is not a report publication announcement (RPA).
2018-09-04 English
FORM 4
Director's Dealing
2018-08-21 English
FORM 4
Director's Dealing
2018-08-15 English
10-Q
Interim / Quarterly Report Q2 2018
2018-08-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.